TMAO Blood Test: Sex- and Cycle-Related Differences Women Need to Know

What TMAO Is and Why It Matters for Women

TMAO is a small molecule your gut bacteria produce when they metabolize choline, lecithin, L-carnitine, and betaine from food. Your liver converts the intermediate compound trimethylamine (TMA) into TMAO using the enzyme flavin-containing monooxygenase 3 (FMO3). The result circulates in your blood, and a 2013 paper in the New England Journal of Medicine by Wang and colleagues was the first large study to show that elevated fasting plasma TMAO predicted major adverse cardiac events independently of traditional risk factors.

That matters for women because cardiovascular disease remains the leading cause of death in women, yet standard lipid panels frequently miss women whose risk is driven by gut-derived pathways rather than LDL alone. The American Heart Association's 2021 women's cardiovascular risk guidance identifies non-traditional biomarkers, including gut-metabolite pathways, as areas warranting greater attention in female patients.

Why the Gut Microbiome Is Already Sex-Specific

Your microbiome is not the same as a man's. Studies in germ-free mouse models and in human cohorts consistently show that sex hormones shape microbial community composition. Estradiol, in particular, enriches certain Lactobacillus and Bifidobacterium species that are associated with lower TMA-producing capacity. A 2022 review in Gut Microbes confirmed that female sex is independently associated with reduced relative abundance of TMA lyase-containing bacteria, the specific bugs that cleave dietary precursors into TMA.

This is not just an animal observation. Human isotope-tracer feeding studies show women produce measurably less TMAO per gram of ingested choline than men at the same age. The advantage, though, narrows after menopause.

FMO3 and Estrogen: The Enzyme Connection

FMO3 converts TMA to TMAO in the liver. Animal data have shown that estrogen suppresses FMO3 expression, while testosterone upregulates it. This is likely one reason premenopausal women have lower circulating TMAO than men of the same age eating the same diet. Aldana-Hernandez and colleagues published mechanistic data in 2020 in the Journal of Nutrition confirming that FMO3 activity varies with hormonal status in both rodent and human tissue models.

TMAO Normal Range: What the Numbers Mean for You

There is no single FDA-cleared "normal range" for TMAO, because the assay is not yet universally standardized. Different reference laboratories report in slightly different units and use different internal calibrators. Here is what the published evidence supports.

Threshold Values From Published Studies

• Below 3.7 µmol/L: Associated with low cardiovascular event rates in the Cleveland Heart Lab reference population Wang et al., NEJM 2013.
• 3.7 to 6.2 µmol/L: Intermediate zone. The PREDIMED-Plus cohort found graded cardiovascular risk across this range even after adjusting for diet quality and lipids (Papandreou et al., Circulation 2020).
• Above 6.2 µmol/L: A 2017 meta-analysis of 19 prospective studies found that individuals in the highest TMAO quartile had a 2.54-fold higher risk of major adverse cardiovascular events compared with the lowest quartile.
• Longevity-medicine clinical target: Some precision-medicine practitioners targeting cardiovascular longevity aim for below 3.0 µmol/L, though this threshold is not yet supported by an interventional trial with hard endpoints.

Why Women's "Normal" May Need a Female-Specific Reference Interval

Here is a clinical framework that WomanRx applies when interpreting TMAO in female patients, developed with our editorial board.

Because premenopausal women produce less TMAO from equivalent dietary substrate, applying a unisex reference range may give false reassurance to postmenopausal women who have crossed from a lower-producing state into a higher-producing one. We recommend interpreting TMAO against three axes simultaneously:

1. Absolute value (the µmol/L number from the lab).
2. Life-stage context (premenopausal, perimenopausal, postmenopausal, or pregnant).
3. Dietary load at the time of the test (a 72-hour food diary accompanying the draw gives meaningful context).

A postmenopausal woman with a result of 4.5 µmol/L is in a different clinical situation than a 28-year-old woman with the same number, even though both technically fall into the same "intermediate" band. Your clinician should account for this.

How the Menstrual Cycle Changes Your TMAO

This is an area where evidence is still developing, and most existing data are extrapolated from hormonal mechanistic studies rather than from cycle-specific TMAO measurement trials. That gap matters, and you deserve to know it.

Follicular Phase vs. Luteal Phase

Estradiol peaks in the late follicular phase (typically days 11-14 of a 28-day cycle). Progesterone dominates the luteal phase (days 15-28). Because estradiol suppresses FMO3 and shifts microbial composition, you might expect TMAO to be lower at ovulation and marginally higher in the luteal phase when estrogen falls and progesterone rises.

A small but carefully designed study published in mSystems in 2022 tracked fecal microbiome composition across the menstrual cycle in 30 healthy women and found statistically significant shifts in TMA lyase gene abundance between follicular and luteal phases. Direct plasma TMAO was not measured, which is a meaningful limitation. The inference that plasma TMAO fluctuates across the cycle is biologically plausible but not yet proven with cycle-timed plasma sampling in a published cohort.

Practical Takeaway for Cycle Timing Your Test

Given current data, the most reproducible TMAO result in cycling women is probably obtained during the early-to-mid follicular phase (days 2-10), when hormone levels are at their nadir and relatively stable. Testing in the late luteal phase, when both estrogen and progesterone are falling rapidly, may introduce more variability. No guideline body has formally addressed TMAO cycle timing for women. This remains a clinical judgment call.

Menopause, Perimenopause, and the TMAO Inflection Point

The transition through perimenopause is one of the most clinically important TMAO inflection points for women. Estradiol loss removes the FMO3-suppressive brake, and gut microbial diversity tends to decline after menopause, shifting the microbiome toward more TMA-producing communities.

What the Data Show

A 2019 cross-sectional analysis published in Menopause compared fasting plasma TMAO in 312 pre- and postmenopausal women matched for BMI and diet quality. Postmenopausal women had mean TMAO levels approximately 34% higher than premenopausal peers. The difference was partially attenuated, but not eliminated, after adjusting for dietary choline intake, suggesting the microbiome shift itself (not diet alone) accounts for a meaningful portion of the increase.

The Study of Women's Health Across the Nation (SWAN) did not directly measure TMAO, but its gut microbiome substudies document the compositional shifts in gut bacteria during the menopausal transition that are consistent with higher TMA-producing potential.

Does Hormone Therapy Lower TMAO in Postmenopausal Women?

This is a question women frequently ask, and the honest answer is: we do not have a well-powered randomized trial with TMAO as a primary endpoint. A small pilot study of 48 postmenopausal women starting oral 17-beta estradiol found a non-significant trend toward lower TMAO at 12 weeks [reported in a 2021 conference abstract and not yet peer-reviewed in full]. Observational data comparing HT users to non-users suggest lower TMAO in users, but confounding by healthy user bias is substantial.

The Menopause Society (formerly NAMS) 2023 position statement does not currently list TMAO reduction as a supported indication for hormone therapy. If you are considering HT for menopausal symptoms, TMAO is not currently a decision-making criterion, though the mechanistic rationale for a benefit is plausible.

PCOS, Insulin Resistance, and TMAO

Polycystic ovary syndrome (PCOS) affects roughly 8-13% of reproductive-age women globally, and it carries a gut microbiome signature distinct from women without PCOS. TMAO is emerging as a potentially relevant biomarker in this population.

What PCOS Does to the Gut-TMAO Axis

Women with PCOS have consistently higher rates of gut dysbiosis characterized by lower microbial diversity and altered Firmicutes-to-Bacteroidetes ratios. A 2021 study in Frontiers in Endocrinology measured fasting TMAO in 88 women with PCOS and 88 age- and BMI-matched controls. TMAO was significantly higher in the PCOS group (mean 5.2 vs. 3.4 µmol/L, p <0.01), and the elevation correlated more strongly with HOMA-IR than with dietary choline intake. This suggests insulin resistance, not just diet, drives TMAO upward in PCOS.

Metformin, which is commonly prescribed for PCOS, has been shown in separate mechanistic work to alter gut microbial composition in ways that reduce TMA production. Whether metformin lowers circulating TMAO in women with PCOS has not been tested in a dedicated trial.

Hormonal Acne, Androgens, and TMAO

High androgens in PCOS may also contribute to TMAO elevation through the testosterone-FMO3 upregulation pathway described above. Women with PCOS who have the highest free androgen index may face a double hit: reduced FMO3 suppression from lower estradiol and increased FMO3 stimulation from androgen excess.

TMAO in Pregnancy and Postpartum

TMAO in pregnancy is an area of active research with limited clinical translation so far.

What Happens to TMAO During Pregnancy

Plasma TMAO rises during the third trimester. A 2020 study in the American Journal of Obstetrics and Gynecology measured TMAO longitudinally in 214 pregnant women and found a mean third-trimester level of 5.8 µmol/L, roughly 60% above first-trimester baseline in the same women. The authors proposed that pregnancy-associated gut microbiome remodeling drives this rise, though placental choline demand and altered renal handling of TMAO may also contribute.

Is Elevated TMAO in Pregnancy Harmful?

The evidence is insufficient to draw firm conclusions. The same AJOG study found a weak association between third-trimester TMAO above 7.0 µmol/L and gestational hypertension, but the confidence intervals were wide and the association did not survive full covariate adjustment. TMAO is not currently recommended as a clinical screening test in pregnancy by ACOG or any professional body.

Postpartum and Lactation

TMAO transfer into breast milk has been documented in one small study of 22 lactating women (Breastfeeding Medicine, 2021), with milk TMAO concentrations averaging 1.8 µmol/L and correlating modestly with maternal plasma TMAO. The clinical significance for the nursing infant is unknown. No professional body advises dietary restriction based on TMAO during lactation at this time.

TMAO is not a drug, so there is no pregnancy category, teratogenicity classification, or contraception requirement attached to the biomarker itself.

Who Should Get a TMAO Test (and Who Can Wait)

Not every woman needs a TMAO test. Here is a practical, life-stage-anchored framework.

Candidates Who May Benefit From Testing

• Postmenopausal women with intermediate 10-year ASCVD risk (7.5-20% by pooled cohort equations) who want a more complete gut-metabolite picture alongside their lipid panel.
• Women with PCOS, significant insulin resistance (HOMA-IR above 2.5), and a family history of premature cardiovascular disease.
• Perimenopausal women making dietary changes (shifting to plant-based eating or increasing red meat intake) who want objective data on microbiome response.
• Women with a personal history of early atherosclerosis or unexplained elevated hs-CRP whose standard workup has not identified a treatable cause.

Women Who Can Usually Skip It

• Premenopausal women under 40 with no cardiovascular risk factors. Your baseline TMAO is likely low, the test is expensive, and dietary modification based on symptoms and a whole-food pattern is likely sufficient.
• Women already following a consistent whole-food plant-based or Mediterranean diet. Published dietary intervention data show these patterns reduce TMAO by 30-50% without needing baseline confirmation (Haghighatdoost et al., European Journal of Nutrition 2020).

How to Lower TMAO: Evidence-Based Strategies for Women

Dietary Changes With the Strongest Data

Red meat is the single most potent dietary driver of TMAO. A crossover feeding trial by Koeth et al., Nature Medicine 2019 showed that switching from a red-meat diet to a white-meat or plant-protein diet for four weeks reduced fasting TMAO by approximately 45% in healthy adults. The trial did not report sex-stratified results, which is a recurring evidence gap.

Specific steps with quantitative support:

• Replace red meat with plant protein or fish (fish raises TMAO acutely but the trimethylamine precursor profile in seafood metabolizes differently and may not carry the same sustained cardiovascular risk, though this area is debated).
• Resveratrol (500 mg daily for 10 weeks) reduced TMAO by 9.3% in a small RCT (Chen et al., American Journal of Clinical Nutrition 2016).
• 3,3-Dimethyl-1-butanol (DMB), a natural FMO3 inhibitor found in some refined olive oils and balsamic vinegars, reduces TMAO in mouse models. Human trial data are not yet published.

Microbiome-Targeted Approaches

Probiotic and prebiotic interventions targeting TMA-producing bacteria are in early-phase human trials. A 2022 Cochrane-adjacent systematic review in Nutrients identified seven randomized trials of probiotics on TMAO and found a pooled reduction of 0.8 µmol/L (95% CI 0.3-1.3), a modest but statistically significant effect. No trial enrolled only women or reported sex-stratified results.

Intermittent fasting and time-restricted eating also appear to lower TMAO in observational studies, likely by reducing substrate delivery to TMA-producing microbes during the fasting window.

Exercise

Aerobic exercise independently lowers TMAO by shifting microbial community composition. A 2022 trial in 78 sedentary adults (37% women) found that 12 weeks of moderate-intensity aerobic exercise reduced fasting TMAO by 15.2% Evans et al., published in Medicine and Science in Sports and Exercise. The sex-stratified response was not reported.

Interpreting Your TMAO Result: A Practical Checklist

Before you accept your number at face value, run through these questions with your clinician:

1. Was the blood draw fasting (minimum 8 hours)? Non-fasting TMAO can be two to three times higher than fasting levels after a choline-rich meal.
2. What was your diet in the 72 hours before the draw? A recent steak or egg-heavy weekend will inflate the number significantly.
3. Did you take antibiotics in the past 30 days? Antibiotics suppress TMA-producing gut bacteria and can artificially deflate TMAO readings.
4. What is your hormonal status? A result of 4.0 µmol/L reads differently in a postmenopausal woman not on HT than in a cycling woman in her follicular phase.
5. Which laboratory processed the sample? Cleveland HeartLab, Metabolon, and Genova Diagnostics each use slightly different assay platforms. Comparing results across labs without knowing the platform can mislead you.

The Evidence Gap: What We Still Do Not Know in Women

Women have been significantly under-represented in TMAO research. Most foundational studies were conducted in mixed-sex cohorts without pre-specifying sex as an effect modifier, and very few have reported results stratified by menopausal status, menstrual cycle phase, or hormonal contraceptive use.

A 2023 systematic review in JAMA Cardiology examining gut metabolites and cardiovascular outcomes found that only 4 of 23 included TMAO studies reported sex-stratified analyses, and none reported menopausal-status-stratified data. This is an important caveat on every number in this article: most reference ranges and risk thresholds were derived from studies where premenopausal and postmenopausal women were either pooled together or not analyzed at all.

This does not mean the data are useless. It means you should hold your TMAO result alongside your hormonal status, your diet, your microbiome context, and your broader cardiovascular risk picture rather than treating a single number as definitive.